AI Engines For more Details: Perplexity Kagi Labs You
Ocular Inflammation: Pranoprofen is indicated for the treatment of inflammation associated with various ocular conditions, including postoperative inflammation following cataract surgery, corneal abrasions, conjunctivitis, and uveitis. By inhibiting the synthesis of prostaglandins, pranoprofen helps reduce inflammation in the eye, alleviating symptoms such as redness, pain, and swelling.
Pain Relief: Pranoprofen provides analgesic (pain-relieving) effects, which can help reduce discomfort and pain associated with ocular inflammation and certain eye injuries or conditions.
Postoperative Care: Pranoprofen is often prescribed as part of postoperative care following ocular surgery, particularly cataract surgery. It helps manage inflammation and discomfort in the eye during the healing process, promoting better outcomes and faster recovery.
Corneal Disorders: Pranoprofen may be used to manage inflammation and pain associated with corneal disorders such as corneal abrasions, keratitis (inflammation of the cornea), and other traumatic or infectious injuries to the cornea.
Conjunctivitis: Pranoprofen can be effective in the treatment of conjunctivitis (pink eye), a common eye condition characterized by inflammation of the conjunctiva (the thin membrane covering the white part of the eye and the inner surface of the eyelids). It helps reduce redness, swelling, and discomfort associated with conjunctivitis.
Uveitis: Uveitis is inflammation of the uvea, the middle layer of the eye. Pranoprofen may be used as part of the treatment regimen for uveitis to reduce inflammation and relieve symptoms such as eye pain, redness, and sensitivity to light.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.1 | 2 |
| Allergies | 0.7 | 0.4 | 0.75 |
| Allergy to milk products | 0.3 | 0.1 | 2 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 0.6 | 0.6 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.3 | 0.33 |
| Ankylosing spondylitis | 0.4 | 0.1 | 3 |
| Anorexia Nervosa | 0.2 | 0.3 | -0.5 |
| Asthma | 0.3 | 0.4 | -0.33 |
| Atherosclerosis | 0.1 | 0.1 | 0 |
| Atrial fibrillation | 0.4 | 0.3 | 0.33 |
| Autism | 0.7 | 0.9 | -0.29 |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Bipolar Disorder | 0.1 | 0.1 | |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.1 | 0.4 | -3 |
| Cerebral Palsy | 0.2 | 0.2 | 0 |
| Chronic Fatigue Syndrome | 0.2 | 0.7 | -2.5 |
| Chronic Kidney Disease | 0.2 | 0.4 | -1 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Urticaria (Hives) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Cognitive Function | 0.1 | 0.1 | |
| Colorectal Cancer | 0.4 | 0.2 | 1 |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0.1 | 0.4 | -3 |
| COVID-19 | 1.1 | 1.6 | -0.45 |
| Crohn's Disease | 0.4 | 0.9 | -1.25 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.1 | 0.1 | 0 |
| Depression | 0.5 | 1 | -1 |
| Endometriosis | 0.3 | 0.3 | |
| Epilepsy | 0.3 | 0.6 | -1 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.4 | 0.1 | 3 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.3 | -2 |
| gallstone disease (gsd) | 0.2 | 0.1 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.3 | 0.2 | 0.5 |
| Gout | 0.3 | 0.1 | 2 |
| Graves' disease | 0.1 | 0.3 | -2 |
| Gulf War Syndrome | 0.2 | 0.4 | -1 |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 0.5 | 0.3 | 0.67 |
| Heart Failure | 0.1 | 0.5 | -4 |
| hemorrhagic stroke | 0 | 0 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 0.1 | 0.6 | -5 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.7 | 0.3 | 1.33 |
| Hypothyroidism | 0.1 | 0.2 | -1 |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.1 | 0.1 | |
| Inflammatory Bowel Disease | 0.4 | 1.2 | -2 |
| Insomnia | 0.3 | 0.7 | -1.33 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.7 | 0.4 | 0.75 |
| ischemic stroke | 0.2 | 0.2 | 0 |
| Liver Cirrhosis | 0.5 | 0.5 | 0 |
| Long COVID | 0.7 | 0.8 | -0.14 |
| Lung Cancer | 0.5 | -0.5 | |
| ME/CFS with IBS | 0.5 | -0.5 | |
| ME/CFS without IBS | 0.2 | -0.2 | |
| Menopause | 0.1 | -0.1 | |
| Metabolic Syndrome | 0.4 | 0.6 | -0.5 |
| Mood Disorders | 0.7 | 0.9 | -0.29 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.2 | -1 |
| Multiple Sclerosis | 0.6 | 0.5 | 0.2 |
| Multiple system atrophy (MSA) | 0.4 | 0.2 | 1 |
| neuropathic pain | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 1.1 | -1.2 |
| NonCeliac Gluten Sensitivity | 0.5 | 0.1 | 4 |
| Obesity | 0.9 | 0.7 | 0.29 |
| obsessive-compulsive disorder | 0.4 | 0.7 | -0.75 |
| Osteoarthritis | 0.4 | 0.2 | 1 |
| Osteoporosis | 0.1 | 0.5 | -4 |
| Parkinson's Disease | 0.9 | 0.9 | 0 |
| Polycystic ovary syndrome | 0.5 | 0.3 | 0.67 |
| Premenstrual dysphoric disorder | 0.2 | 0.2 | |
| primary biliary cholangitis | 0 | 0 | |
| Primary sclerosing cholangitis | 0.1 | 0.5 | -4 |
| Psoriasis | 0.4 | 0.5 | -0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.5 | 0 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.5 | 0.3 | 0.67 |
| Sjögren syndrome | 0.2 | 0.4 | -1 |
| Sleep Apnea | 0.2 | 0.2 | 0 |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.3 | -0.5 |
| Systemic Lupus Erythematosus | 0.2 | 0.2 | 0 |
| Tic Disorder | 0 | 0 | |
| Tourette syndrome | 0.2 | 0.1 | 1 |
| Type 1 Diabetes | 0.5 | 0.1 | 4 |
| Type 2 Diabetes | 0.5 | 0.6 | -0.2 |
| Ulcerative colitis | 0.5 | 0.4 | 0.25 |
| Unhealthy Ageing | 0.2 | 0.3 | -0.5 |
| Vitiligo | 0.1 | 0.1 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
